Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Alkermes plc
Type
Public NASDAQ: ALKS
Industry Biotechnology
Headquarters Dublin, Ireland
Key people
Richard Pops, CEO
Revenue Increase US$187 Million
Operating income
Decrease US$-42.9 Million
Net income
Decrease US$-39.6 Million
Total assets Decrease US$452 Million
Total equity Decrease US$392 Million
Number of employees
1200
Website www.alkermes.com

Alkermes plc is a biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger in September 2011 between Alkermes, Inc., and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.

Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases, such as addiction, schizophrenia, diabetes and depression. Among these products, five are primary to the company: risperidone long-acting Injection (generic for Risperdal Consta) for schizophrenia and bipolar 1 disorder, paliperidone palmitate (generic for Invega Sustenna in the U.S., Xeplion in Europe) for schizophrenia, 4-aminopyridine (generic for Ampyra in the U.S., Fampyra in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension (generic for Vivitrol) for alcohol and opioid dependence, and exenatide extended-release for injectable suspension (generic for Bydureon) for the treatment of type 2 diabetes. Bydureon is a once-weekly, extended-release form of the drug, exenatide (Byetta), and was developed through a partnership between Amylin Pharmaceuticals, Alkermes and Eli Lilly. It is approved in Europe and the U.S.

Buprenorphine/samidorphan (ALKS-5461), a κ-opioid receptor antagonist, is a next-generation, novel antidepressant which is under development by Alkermes for treatment-resistant depression.

Olanzapine/samidorphan (ALKS-3831) is an atypical antipsychotic and opioid modulator combination that is under development for the treatment of schizophrenia and bipolar mania.

Investment goal date:
Dividends reinvested
Alkermes plc ALKS report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-30
--
--
Q4 2017
2018-02-13
--
--
Q3 2017
2017-10-26
0.0300
-0.2400
Q2 2017
2017-07-27
0.0100
-0.2800
Q1 2017
2017-04-27
-0.1800
-0.4500
Q4 2016
2017-02-15
0.0200
-0.1400
Q3 2016
2016-11-02
-0.0900
-0.4100
Q2 2016
2016-07-28
-0.0100
-0.3100
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
1354087
BlackRock Fund Advisors
3718835
BlackRock Inc.
10292601
BlackRock Institutional Trust Company, N.A.
4073024
FMR LLC
22882118
FRANKLIN RESOURCES INC
2476000
GOLDMAN SACHS GROUP INC
2857077
Invesco Ltd.
5053331
JANUS CAPITAL MANAGEMENT LLC
1658928
PRICE T ROWE ASSOCIATES INC /MD/
18724454
PRIMECAP MANAGEMENT CO/CA/
7856543
STATE STREET CORP
3974002
Vanguard Group, Inc
12096635
WADDELL & REED FINANCIAL INC
1814620
WELLINGTON MANAGEMENT CO LLP
20021376
Major Shareholders
Name Relationship
Total Shares
Holding stocks
POPS RICHARD F
0.4400% (637686)
ALKS / EPZM / NBIX / XLRN /
ANSTICE DAVID W
0.0100% (15000)
ALKS /
BIBERSTEIN KATHRYN L
0.0400% (60976)
ALKS /
FRATES JAMES M
0.0900% (129477)
ALKS / SAGE /
FRATES JAMES M
0.1000% (144039)
ALKS / SAGE /
LANDINE MICHAEL J
0.1100% (163693)
ALKS / KOPN /
BLOOM FLOYD E
0.0100% (20000)
ALKS /
MITCHELL PAUL J
0.0100% (8000)
ALKS /
Pugh Gordon G
0.0100% (20587)
ALKS /
Ehrich Elliot
0.0400% (57056)
ALKS /
Stejbach Mark
0.0300% (44013)
ALKS / FLXN / TNGN /
Cooke Shane
0.0500% (74708)
ALKS / PRTA /
Brown Iain Michael
0.0200% (27595)
ALKS /
% ()